ArticleBiosensors2025
Fumonisin B Determination in Maize Products from Belize Using an Immunosensor Based on Screen-Printed Carbon Electrodes.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A competitive electrochemical immunosensor, using screen-printed carbon electrodes (SPCEs), was developed for the determination of total fumonisins (sum of FB1, FB2 and FB3) extracted with a simple solvent extraction and dilution method, without clean up, from maize flour and maize tortillas. The optimized biosensor has a linear range of 0.25 to 50 µg/L with 3% and 2% reproducibility for FB1 and (FB1 + FB2), respectively, and a linear range of 0.25 to 10 µg/L with 2% reproducibility for (FB1 + FB2 + FB3). The limits of detection and quantification in PBS buffer for total fumonisins are 0.12 µg/L and 0.39 µg/L, respectively. These values in the maize matrix are 6.07 µg/kg and 20.25 µg/kg, respectively. In addition, the stability and the selectivity of the sensor were studied. The immunosensor was validated with liquid chromatography-tandem mass spectrometry. This novel biosensor is more rapid, simpler and cheaper than current methods, and can also be used at the point of need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.